organization · Reporting owner

Atlas Venture Associates IX, LLC

Disclosed activity across 4 companies

Tapewire entity: 105946
SEC CIK: 0001671207

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cogent Biosciences, Inc.UMRX · Entity 3793	10% owner	April 03, 2018	April 03, 2018
Intellia Therapeutics, Inc.NTLA · Entity 4585	10% owner	July 07, 2017	July 11, 2017
Spero Therapeutics, Inc.SPRO · Entity 7014	10% owner	November 01, 2017	November 01, 2017
Surface Oncology, Inc.SURF · Entity 109857	10% owner	December 17, 2020	December 21, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cogent Biosciences, Inc.

Report date April 03, 2018 · Filed April 03, 2018

Jointly reported with Atlas Venture Fund IX, L.P., Atlas Venture Associates IX, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,361,535	Last balance in matching sequence After 2018-04-03 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2018-04-03 · Conversion · Acquired 3,184,446 · Balance 3,184,446 F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Row 2 · 2018-04-03 · Conversion · Acquired 83,037 · Balance 3,267,483 F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Row 3 · 2018-04-03 · Purchase · Acquired 94,052 · Balance 3,361,535 F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-04-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-04-03 · Conversion · Disposed 3,184,446 · Balance 0 F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-04-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-04-03 · Conversion · Disposed 83,037 · Balance 0 F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.

Intellia Therapeutics, Inc.

Report date July 07, 2017 · Filed July 11, 2017

Jointly reported with Atlas Venture Fund IX, L.P., Atlas Venture Associates IX, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,579,788	Last balance in matching sequence After 2017-07-11 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2017-07-07 · Sale · Disposed 30,000 · Balance 3,699,788 F1: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. F5: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any. Row 2 · 2017-07-10 · Sale · Disposed 40,000 · Balance 3,659,788 F1: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4. F5: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any. Row 3 · 2017-07-11 · Sale · Disposed 80,000 · Balance 3,579,788 F1: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4. F5: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

F5: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any.

Spero Therapeutics, Inc.

Report date November 01, 2017 · Filed November 01, 2017

Jointly reported with Atlas Venture Fund IX, L.P., Atlas Venture Associates IX, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,781	Reported balance Holding disclosure · report date 2017-11-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 42,781 F1: The number of shares reported reflects a 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.
Junior Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: The shares of Junior preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F4: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F5: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F6: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017. F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The number of shares reported reflects a 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

F2: The shares of Junior preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

F4: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F6: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F7: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims beneficial ownership of the shares held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein.

Surface Oncology, Inc.

Report date December 17, 2020 · Filed December 21, 2020 · Amendment

Jointly reported with Atlas Venture Fund IX, L.P., Atlas Venture Associates IX, L.P.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,945,453	Reported balance After 2020-12-17 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2020-12-17 · Sale · Disposed 1,700,000 · Balance 2,945,453 F1: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2: The high, low and average for the shares sold were all $8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. F4: This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from $18.10 to $8.10. F3: Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2: The high, low and average for the shares sold were all $8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

F3: Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any.

F4: This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from $18.10 to $8.10.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 17, 2020 Filed Dec 21, 2020 15:35 UTC Amendment	Surface Oncology, Inc. SURF · Entity 109857	SaleCommon Stock	1,700,000	$8.10	$13,770,000.00	Disclosure SEC source: 0001104659-20-138021 · a4a.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,945,453 F1 · shares: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · price: The high, low and average for the shares sold were all $8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. F4 · price: This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from $18.10 to $8.10. F3 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any. Read SEC document
December 17, 2020 Filed Dec 21, 2020 13:32 UTC	Surface Oncology, Inc. SURF · Entity 109857	SaleCommon Stock	1,700,000	$18.10	$30,770,000.00	Disclosure SEC source: 0001104659-20-137966 · a4.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,945,453 F1 · shares: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · price: The high, low and average for the shares sold were all $8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. F3 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any. Read SEC document
April 23, 2018 Filed Apr 23, 2018 16:18 UTC	Surface Oncology, Inc. SURF · Entity 109857	ConversionSeries A Preferred Stock · Derivative	7,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-025826 · doc4.xml · derivative · entry 3 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,181,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.underlying_shares: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 23, 2018 Filed Apr 23, 2018 16:18 UTC	Surface Oncology, Inc. SURF · Entity 109857	PurchaseCommon Stock	100,000	$15.00	$1,500,000.00	Disclosure SEC source: 0001209191-18-025826 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,645,453 F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 23, 2018 Filed Apr 23, 2018 16:18 UTC	Surface Oncology, Inc. SURF · Entity 109857	ConversionCommon Stock	3,181,817	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-025826 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 03, 2018 Filed Apr 3, 2018 17:11 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	ConversionSeries B Preferred Stock · Derivative	83,037	$0.00	$0.00	Disclosure SEC source: 0000899243-18-009264 · doc4.xml · derivative · entry 5 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 03, 2018 Filed Apr 3, 2018 17:11 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	ConversionSeries A Preferred Stock · Derivative	3,184,446	$0.00	$0.00	Disclosure SEC source: 0000899243-18-009264 · doc4.xml · derivative · entry 4 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,184,446 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 03, 2018 Filed Apr 3, 2018 17:11 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	PurchaseCommon Stock	94,052	$12.00	$1,128,624.00	Disclosure SEC source: 0000899243-18-009264 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361,535 F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 03, 2018 Filed Apr 3, 2018 17:11 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	ConversionCommon Stock	83,037	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009264 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,267,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
April 03, 2018 Filed Apr 3, 2018 17:11 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	ConversionCommon Stock	3,184,446	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-009264 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,184,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
July 11, 2017 Filed Jul 11, 2017 17:37 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	SaleCommon Stock	80,000	$16.07	$1,285,560.00	Disclosure SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 3 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,579,788 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4. F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
July 10, 2017 Filed Jul 11, 2017 17:37 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	SaleCommon Stock	40,000	$16.17	$646,888.00	Disclosure SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 2 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,659,788 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4. F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
July 07, 2017 Filed Jul 11, 2017 17:37 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	SaleCommon Stock	30,000	$16.77	$502,992.00	Disclosure SEC source: 0001104659-17-044529 · a4.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,699,788 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. F5 · ownership.direct: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any. Read SEC document
March 10, 2017 Filed Mar 13, 2017 10:39 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	SaleCommon Stock	5,504	$14.06	$77,410.46	Disclosure SEC source: 0001209191-17-020055 · doc4.xml · nonDerivative · entry 2 Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP, and disclaims Section 16 beneficial ownership of the securities held by AVA IX LP, except to the extent of its pecuniary interest therein, if any. On March 3, 2017 AVA IX LP received 21,132 shares of the issuer's common stock from Atlas Venture Fund IX, L.P. (the "Fund") in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.86 - $14.33, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4. Read SEC document
March 09, 2017 Filed Mar 13, 2017 10:39 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	SaleCommon Stock	15,628	$13.85	$216,432.17	Disclosure SEC source: 0001209191-17-020055 · doc4.xml · nonDerivative · entry 1 Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,504 F1 · security: Represents shares sold by Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP, and disclaims Section 16 beneficial ownership of the securities held by AVA IX LP, except to the extent of its pecuniary interest therein, if any. On March 3, 2017 AVA IX LP received 21,132 shares of the issuer's common stock from Atlas Venture Fund IX, L.P. (the "Fund") in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 - $14.02, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. Read SEC document
March 03, 2017 Filed Mar 7, 2017 08:35 UTC	Intellia Therapeutics, Inc. NTLA · Entity 4585	OtherCommon Stock	700,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-018547 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund IX, L.P. · CIK 0001671219 · 10% owner Atlas Venture Associates IX, L.P. · CIK 0001671208 · 10% owner Atlas Venture Associates IX, LLC · CIK 0001671207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,729,788 F1 · kind: On March 3, 2017, Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. ("AVA IX LP"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act"). F1 · price: On March 3, 2017, Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. ("AVA IX LP"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Act"). F2 · ownership.direct: The shares are held directly by Atlas Venture Fund IX. Each of AVA IX LP and Atlas Venture Associates IX, LLC, its general partner ("AVA IX LLC") disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.